MARÍA
CALLEJO ARRANZ
Investigadora predoctoral
Centro Nacional de Investigaciones Cardiovasculares Carlos III
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Centro Nacional de Investigaciones Cardiovasculares Carlos III (6)
2023
-
Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model (Frontiers in Pharmacology, (2023), 14, (1021535), 10.3389/fphar.2023.1021535)
Frontiers in Pharmacology
-
Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model
Frontiers in Pharmacology, Vol. 14
2021
-
Oxygen-sensitivity and pulmonary selectivity of vasodilators as potential drugs for pulmonary hypertension
Antioxidants, Vol. 10, Núm. 2, pp. 1-14
-
Restoration of vitamin d levels improves endothelial function and increases task-like k+ currents in pulmonary arterial hypertension associated with vitamin d deficiency
Biomolecules, Vol. 11, Núm. 6
2020
-
Uncovered Contribution of Kv7 Channels to Pulmonary Vascular Tone in Pulmonary Arterial Hypertension
Hypertension, Vol. 76, Núm. 4, pp. 1134-1146
2018
-
Pulmonary Arterial Hypertension Affects the Rat Gut Microbiome
Scientific Reports, Vol. 8, Núm. 1